Chapter 1 Prefix
    1.1 Market Scope
    1.2 Report Description
    1.3 Research Methodology
          1.3.1 Primary Research
          1.3.2 Secondary Research
          1.3.3 In-house Data Modeling
Chapter 2 Executive Summary
Chapter 3 Market Outline
    3.1 Market Inclination, Trend, Outlook and Viewpoint
    3.2 Market Share Analysis: Company’s Competitive Scenario
    3.3 Market Dynamics
          3.3.1 Drivers
                   3.3.1.1 Impact Analysis
          3.3.2 Restraints
                   3.3.2.1 Impact Analysis
          3.3.3 Opportunities
Chapter 4 Diabetic Nephropathy Market by Mode of Treatment: Market Size and Forecast, 2015 – 2024
    4.1 Overview
    4.2 Drug Modifying Therapies (DMT)
          4.2.1 Current Trend and Analysis
          4.2.2 Market Size and Forecast
          4.2.3 Angiotensin-Converting Enzyme (ACE) Inhibitor
                   4.2.3.1 Market Size and Forecast
          4.2.4 Angiotensin Receptor Blockers (ARBs)
                   4.2.4.1 Market Size and Forecast
          4.2.5 Diuretics
                   4.2.5.1 Market Size and Forecast
          4.2.6 Calcium Channel Blockers (CCBs)
                   4.2.6.1 Market Size and Forecast
          4.2.7 Renin Inhibitors
                   4.2.7.1 Market Size and Forecast
          4.2.8 Connective Tissue Growth Factor Inhibitor (CTGF)
                   4.2.8.1 Market Size and Forecast
          4.2.9 Antioxidant Inflammation Modulator (AIM)
                   4.2.9.1 Market Size and Forecast
          4.2.10 Monocyte Chemoattractant Proteins (MCP) Inhibitors
                   4.2.10.1 Market Size and Forecast
          4.2.11 Endothelin-A Receptors Antagonist (ETAR)
                   4.2.11.1 Market Size and Forecast
          4.2.12 G Protein-Coupled Receptors (GPCRs)
                   4.2.12.1 Market Size and Forecast
          4.2.13 Other Drug Modifying Therapies
                   4.2.13.1 Market Size and Forecast
    4.3 Other Drug Modifying Therapies
          4.3.1 Current Trend and Analysis
          4.3.2 Market Size and Forecast
Chapter 5 Diabetic Nephropathy Market by Geography: Market Size and Forecast, 2015 – 2024
    5.1 Overview
    5.2 North America
          5.2.1 Current Trend and Analysis
          5.2.2 Market Size and Forecast
          5.2.3 US
                   5.2.3.1 Market Size and Forecast
          5.2.4 Canada
                   5.2.4.1 Market Size and Forecast
          5.2.5 Mexico
                   5.2.5.1 Market Size and Forecast
    5.3 Europe
          5.3.1 Current Trend and Analysis
          5.3.2 Market Size and Forecast
          5.3.3 UK
                   5.3.3.1 Market Size and Forecast
          5.3.4 Germany
                   5.3.4.1 Market Size and Forecast
          5.3.5 France
                   6.3.5.1 Market Size and Forecast
          5.3.6 Italy
                   6.3.6.1 Market Size and Forecast
          5.3.6 Others
                   5.3.6.1 Market Size and Forecast
    5.4 Asia-Pacific
          5.4.1 Current Trend and Analysis
          5.4.2 Market Size and Forecast
          5.4.3 China
                   5.4.3.1 Market Size and Forecast
          5.4.4 India
                   5.4.4.1 Market Size and Forecast
          5.4.5 Japan
                   5.4.5.1 Market Size and Forecast
          5.4.6 South Korea
                   5.4.6.1 Market Size and Forecast
          5.4.6 Others
                   5.4.6.1 Market Size and Forecast
    5.5 RoW
          5.5.1 Current Trend and Analysis
          5.5.2 Market Size and Forecast
          5.5.3 Middle East
                   5.5.3.1 Market Size and Forecast
          5.5.4 South America
                   5.5.4.1 Market Size and Forecast
          5.5.5 Africa
                   5.5.5.1 Market Size and Forecast
Chapter 6 Company Profiles
    6.1 Bayer AG
    6.2  Novartis AG
    6.3 Eli Lilly and Company
    6.4 Mallinckrodt Pharmaceuticals
    6.5 Mitsubishi Tanabe Pharma Corporation
    6.6 Mesoblast Ltd.
    6.7 Ampio Pharmaceuticals Inc.
    6.8 Reata Pharmaceuticals
    6.9 GenKyoTex S.A.
    6.10 ChemoCentryx Inc.

GET MORE INFORMATION ABOUT THIS REPORT


Refresh Captcha

Related Report